This HTML5 document contains 46 embedded RDF statements represented using HTML+Microdata notation.

The embedded RDF content will be recognized by any processor of HTML5 Microdata.

Namespace Prefixes

PrefixIRI
n10http://linked.opendata.cz/resource/drugbank/drug/DB04886/identifier/kegg-compound/
n2http://linked.opendata.cz/resource/drugbank/drug/
dctermshttp://purl.org/dc/terms/
n8http://linked.opendata.cz/resource/drugbank/drug/DB04886/identifier/bindingdb/
n11http://linked.opendata.cz/resource/drugbank/drug/DB04886/identifier/pubchem-compound/
n9http://linked.opendata.cz/resource/drugbank/drug/DB04886/identifier/pubchem-substance/
n7http://linked.opendata.cz/resource/drugbank/drug/DB04886/identifier/drugbank/
n14http://bio2rdf.org/drugbank:
admshttp://www.w3.org/ns/adms#
n4http://linked.opendata.cz/resource/drugbank/drug/DB04886/identifier/chemspider/
rdfhttp://www.w3.org/1999/02/22-rdf-syntax-ns#
owlhttp://www.w3.org/2002/07/owl#
n5http://linked.opendata.cz/ontology/drugbank/
n6http://linked.opendata.cz/resource/drugbank/property/
xsdhhttp://www.w3.org/2001/XMLSchema#

Statements

Subject Item
n2:DB04886
rdf:type
n5:Drug
n5:description
Calanolide A is a new non-nucleoside reverse transcriptase inhibitor (NNRTI) derived from a plant found in the Malaysian rain forest. A related compound, calanolide B, also has anti-HIV activity. Both drugs are being developed by Sarawak Pharmaceuticals. A preliminary dosing study among HIV-infected individuals showed a significant antiviral effect compared with placebo.
n5:generalReferences
# Eiznhamer DA, Creagh T, Ruckle JL, Tolbert DT, Giltner J, Dutta B, Flavin MT, Jenta T, Xu ZQ: Safety and pharmacokinetic profile of multiple escalating doses of (+)-calanolide A, a naturally occurring nonnucleoside reverse transcriptase inhibitor, in healthy HIV-negative volunteers. HIV Clin Trials. 2002 Nov-Dec;3(6):435-50. "Pubmed":http://www.ncbi.nlm.nih.gov/pubmed/12501127 # Xu ZQ, Barrow WW, Suling WJ, Westbrook L, Barrow E, Lin YM, Flavin MT: Anti-HIV natural product (+)-calanolide A is active against both drug-susceptible and drug-resistant strains of Mycobacterium tuberculosis. Bioorg Med Chem. 2004 Mar 1;12(5):1199-207. "Pubmed":http://www.ncbi.nlm.nih.gov/pubmed/14980631 # Sekino E, Kumamoto T, Tanaka T, Ikeda T, Ishikawa T: Concise synthesis of anti-HIV-1 active (+)-inophyllum B and (+)-calanolide A by application of (-)-quinine-catalyzed intramolecular oxo-Michael addition. J Org Chem. 2004 Apr 16;69(8):2760-7. "Pubmed":http://www.ncbi.nlm.nih.gov/pubmed/15074925
n5:group
investigational
n5:halfLife
20 hours for 800mg
n5:indication
For use in combination treatment of HIV infection (AIDS).
owl:sameAs
n14:DB04886
dcterms:title
Calanolide A
adms:identifier
n4:58497 n7:DB04886 n8:50002662 n9:11339 n10:C09147 n11:64972
n5:mechanismOfAction
Viral life-cycle studies indicate that calanolide A acts early in the infection process, similar to the known HIV reverse transcriptase (RT) inhibitor 2', 3'-dideoxycytidine. In enzyme inhibition assays, calanolide A potently and selectively inhibits recombinant HIV type 1 RT but not cellular DNA polymerases or HIV type 2 RT within the concentration range tested.
n5:synonym
(+/-)-calanolide A (+)-calanolide A
n5:IUPAC-Name
n6:271B5D10-363D-11E5-9242-09173F13E4C5
n5:InChI
n6:271B5D16-363D-11E5-9242-09173F13E4C5
n5:Molecular-Formula
n6:271B5D15-363D-11E5-9242-09173F13E4C5
n5:Molecular-Weight
n6:271B5D12-363D-11E5-9242-09173F13E4C5
n5:Monoisotopic-Weight
n6:271B5D13-363D-11E5-9242-09173F13E4C5
n5:SMILES
n6:271B5D14-363D-11E5-9242-09173F13E4C5
n5:Water-Solubility
n6:271B5D0E-363D-11E5-9242-09173F13E4C5
n5:logP
n6:271B5D0F-363D-11E5-9242-09173F13E4C5 n6:271B5D0C-363D-11E5-9242-09173F13E4C5
n5:logS
n6:271B5D0D-363D-11E5-9242-09173F13E4C5
n5:H-Bond-Acceptor-Count
n6:271B5D1C-363D-11E5-9242-09173F13E4C5
n5:H-Bond-Donor-Count
n6:271B5D1D-363D-11E5-9242-09173F13E4C5
n5:InChIKey
n6:271B5D17-363D-11E5-9242-09173F13E4C5
n5:Polar-Surface-Area--PSA-
n6:271B5D18-363D-11E5-9242-09173F13E4C5
n5:Polarizability
n6:271B5D1A-363D-11E5-9242-09173F13E4C5
n5:Refractivity
n6:271B5D19-363D-11E5-9242-09173F13E4C5
n5:Rotatable-Bond-Count
n6:271B5D1B-363D-11E5-9242-09173F13E4C5
n5:affectedOrganism
Human Immunodeficiency Virus
n5:casRegistryNumber
142632-32-4
n5:category
n5:Bioavailability
n6:271B5D22-363D-11E5-9242-09173F13E4C5
n5:Ghose-Filter
n6:271B5D24-363D-11E5-9242-09173F13E4C5
n5:MDDR-Like-Rule
n6:271B5D25-363D-11E5-9242-09173F13E4C5
n5:Number-of-Rings
n6:271B5D21-363D-11E5-9242-09173F13E4C5
n5:Physiological-Charge
n6:271B5D20-363D-11E5-9242-09173F13E4C5
n5:Rule-of-Five
n6:271B5D23-363D-11E5-9242-09173F13E4C5
n5:Traditional-IUPAC-Name
n6:271B5D11-363D-11E5-9242-09173F13E4C5
n5:pKa--strongest-acidic-
n6:271B5D1E-363D-11E5-9242-09173F13E4C5
n5:pKa--strongest-basic-
n6:271B5D1F-363D-11E5-9242-09173F13E4C5